Abstract

BackgroundIt is now clearly evident that cancer outcome and response to therapy is guided by diverse immune-cell activity in tumors. Presently, a key challenge is to comprehensively identify networks of distinct immune-cell signatures present in complex tissue, at higher-resolution and at various stages of differentiation, activation or function. This is particularly so for closely related immune-cells with diminutive, yet critical, differences.ResultsTo predict networks of infiltrated distinct immune-cell phenotypes at higher resolution, we explored an integrated knowledge-based approach to select immune-cell signature genes integrating not only expression enrichment across immune-cells, but also an automatic capture of relevant immune-cell signature genes from the literature. This knowledge-based approach was integrated with resources of immune-cell specific protein networks, to define signature genes of distinct immune-cell phenotypes. We demonstrate the utility of this approach by profiling signatures of distinct immune-cells, and networks of immune-cells, from metastatic melanoma patients who had undergone chemotherapy. The resultant bioinformatics strategy complements immunohistochemistry from these tumors, and predicts both tumor-killing and immunosuppressive networks of distinct immune-cells in responders and non-responders, respectively. The approach is also shown to capture differences in the immune-cell networks of BRAF versus NRAS mutated metastatic melanomas, and the dynamic changes in resistance to targeted kinase inhibitors in MAPK signalling.ConclusionsThis integrative bioinformatics approach demonstrates that capturing the protein network signatures and ratios of distinct immune-cell in the tumor microenvironment maybe an important factor in predicting response to therapy. This may serve as a computational strategy to define network signatures of distinct immune-cells to guide immuno-pathological discovery.Electronic supplementary materialThe online version of this article (doi:10.1186/s12859-016-1141-3) contains supplementary material, which is available to authorized users.

Highlights

  • It is clearly evident that cancer outcome and response to therapy is guided by diverse immune-cell activity in tumors

  • A bioinformatics pipeline to identify signature genes from transcriptomes of distinct immune-cells First, signature genes associated to general immune-cell types (GIT) were extracted from Medline

  • These GIT genes are used to generate an extended list of genes signifying an association to their corresponding distinct immune-cell phenotypes (DIST)

Read more

Summary

Introduction

It is clearly evident that cancer outcome and response to therapy is guided by diverse immune-cell activity in tumors. A key challenge is to comprehensively identify networks of distinct immune-cell signatures present in complex tissue, at higher-resolution and at various stages of differentiation, activation or function This is so for closely related immune-cells with diminutive, yet critical, differences. Clancy and Hovig BMC Bioinformatics (2016) 17:263 benefit to automatically and systematically investigate the presence of immune-cell networks in tumors with improved fidelity; i.e. to painstakingly profile a tumor for diverse, precisely defined, distinct immune-cells (such as distinct phenotypes of effector CD8+ T cells profiled at high-resolution), rather than general immune-cell types, or generic associations to immune-cells such as “protumor” and “antitumor” [22, 24] To achieve this efficiently, many systems-immunology challenges need to be overcome; whereby the guidance of improved computational pipelines are needed [21, 25,26,27]. The framework attempts to improve general definitions of immune signatures (such as CD4+ T cells, CD8+ T cells, NK cells, etc.), and offers the possibility to query wide ranges of DISTs in their tumor contexts at multiple stages of differentiation, activation or function

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call